![Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/81ea0360-383c-467c-9443-bd82ff7868fb/gr1.jpg)
Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d0668b16-6f13-4a1b-99c6-7416a2f7b1b3/ctm2346-fig-0002-m.jpg)
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
![Inflammation and tumor progression: signaling pathways and targeted intervention | Signal Transduction and Targeted Therapy Inflammation and tumor progression: signaling pathways and targeted intervention | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-021-00658-5/MediaObjects/41392_2021_658_Fig1_HTML.png)
Inflammation and tumor progression: signaling pathways and targeted intervention | Signal Transduction and Targeted Therapy
OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
![Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020) Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)](https://jnccn.org/view/journals/jnccn/18/12.5/full-jnccn20-5043f1.jpg)
Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)
![PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma](https://i1.rgstatic.net/publication/326430488_Serum_free_light_chain_levels_and_renal_function_at_diagnosis_in_patients_with_multiple_myeloma/links/5b4d59a7a6fdcc8dae2468c2/largepreview.png)
PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
![Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-98803-1/MediaObjects/41598_2021_98803_Fig1_HTML.png)
Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients](https://www.frontiersin.org/files/Articles/575168/fonc-10-575168-HTML/image_m/fonc-10-575168-t002.jpg)
Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![Cardiac amyloidosis: An underdiagnosed/underappreciated disease - European Journal of Internal Medicine Cardiac amyloidosis: An underdiagnosed/underappreciated disease - European Journal of Internal Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d2244edd-6b22-42be-8289-107cdd8d83d7/ga1_lrg.jpg)
Cardiac amyloidosis: An underdiagnosed/underappreciated disease - European Journal of Internal Medicine
![All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1613cdc1-b321-464f-b17b-ec4249d7b88e/gr1_lrg.jpg)
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer
![Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/537b0efd-b55e-413f-bb35-9d1e7f18bd3c/gr1_lrg.jpg)
Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients](https://www.frontiersin.org/files/Articles/575168/fonc-10-575168-HTML/image_m/fonc-10-575168-g001.jpg)